Analysts at Guggenheim initiated coverage on shares of ADC Therapeutics (NYSE:ADCT – Get Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The firm set a “buy” rating and a $11.00 price target on the stock. Guggenheim’s target price would suggest a potential upside of 161.90% from the company’s current price.
Several other brokerages have also weighed in on ADCT. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of ADC Therapeutics in a research report on Wednesday, March 6th. Royal Bank of Canada restated an “outperform” rating and issued a $8.00 price target on shares of ADC Therapeutics in a research note on Thursday, March 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $7.50.
Check Out Our Latest Stock Analysis on ADC Therapeutics
ADC Therapeutics Stock Down 3.4 %
Hedge Funds Weigh In On ADC Therapeutics
Several hedge funds have recently bought and sold shares of ADCT. Prospera Financial Services Inc bought a new position in ADC Therapeutics in the 1st quarter valued at about $25,000. HRT Financial LP bought a new position in ADC Therapeutics in the 1st quarter valued at about $31,000. Saxony Capital Management LLC bought a new position in ADC Therapeutics in the 4th quarter valued at about $34,000. Quantbot Technologies LP bought a new position in ADC Therapeutics in the 2nd quarter valued at about $38,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of ADC Therapeutics by 1,253.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock valued at $46,000 after purchasing an additional 8,773 shares during the last quarter. 41.10% of the stock is owned by institutional investors.
ADC Therapeutics Company Profile
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Recommended Stories
- Five stocks we like better than ADC Therapeutics
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- What Investors Need to Know About Upcoming IPOs
- 7 Stocks That Will Drive the Weight Loss Drugs Market
- What is a Dividend King?
- Cintas or UniFirst: Investors Win Either Way
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.